search
Back to results

Efficacy and Tolerability of Antistax® in Male and Female Patients Suffering From Chronic Venous Insufficiency

Primary Purpose

Venous Insufficiency

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Antistax®
Placebo
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Venous Insufficiency

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female
  • 18 years of age or older
  • CVI, Clinical Class 3 (oedema) or 4a (mild skin changes ascribed to venous disease, e.g. pigmentation), according to the CEAP classification
  • Willing and able to give written informed consent prior to participation in the study

Exclusion Criteria:

Concomitant diseases:

  • Decompensated cardiac insufficiency
  • Oedema not due to venous disease of the legs (e.g., latent cardiac insufficiency, renal insufficiency, lymphoedema, etc)
  • Peripheral arterial disease (ankle/arm pressure index < 0.9)
  • Current acute phlebitis or thrombosis
  • Renal insufficiency (serum creatinine > 1.5 mg/dl)
  • Liver disease (SGPT > 3x upper limit of normal)
  • Other diseases: hyper- or hypocalcaemia, malignancies
  • Anamnestic indications of diabetic microangiopathy or polyneuropathy
  • Drug and/or alcohol abuse
  • Severe climacteric complaints: changes in, or initiation with post-menopausal hormone replacement therapy within the last 3 months
  • Immobility
  • Avalvulia
  • Klippel-Trénaunay-Weber-Syndrome (Naevus varicosis osteohypertrophicus, Haemangiectasia hypertrophicans)
  • State after pulmonary embolism
  • Recognised hypersensitivity to the trial drug ingredients
  • Current florid venous ulcus
  • Clinical indication for a necessary, specific phlebologic acute treatment, e.g. compression treatment, phlebectomy, etc.

Previous treatments:

  • Patients who are on compression therapy and/or are wearing support stockings and who optimally benefit from these measures
  • Treatment with venous drugs within the last 2 weeks prior to the intake of study medication
  • Changes in or unstable response to treatment with theophylline, diuretics, cardiac glycosides, ACE inhibitors, calcium antagonists, or laxatives within the last 2 weeks prior to the intake of study medication

Concomitant treatment/non-drug therapy exclusion criteria:

  • Other venous drugs apart from the trial medication
  • Venous surgery or sclerotherapy within the last 12 month at the leg used for volumetry
  • Extensive use of laxatives
  • Major surgery requiring full anaesthesia

Other exclusion criteria:

  • Previously studied under this protocol
  • Participation in another clinical trial within the previous 90 days or during the present study
  • Patient is investigator, co-investigator, or study nurse in this study
  • Pregnant or nursing women or inadequate birth control methods (this applies to females of childbearing potential only)
  • Patients considered as mentally ill as well as unable to work or with limited working ability, or unable (or only partially able) to follow the spoken or written explanations concerning the trial
  • Patients in a bad general health state according to the investigator's judgement

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Antistax®

    Placebo

    Arm Description

    1 tablet per day for 12 weeks

    Outcomes

    Primary Outcome Measures

    Change from baseline in limb volume determination
    water displacement method

    Secondary Outcome Measures

    Changes in limb volume determination
    water displacement method
    Changes in the calf circumference
    in centimeters
    Changes in the ankle circumference
    in centimeters
    Changes in the subjective symptoms of CVI measured by Visual Analogue Scales (VAS)
    Global assessment of efficacy by the patient on a 4-point verbal rating scale (VRS)
    Global assessment of efficacy by the investigator on a 4-point VRS
    Global assessment of tolerability by the patient on a 4-point VRS
    Global assessment of tolerability by the investigator on a 4-point VRS
    Number of patients with adverse events
    Number of patients with clinically significant changes in laboratory values
    Number of patients with clinically significant changes in vital signs (Blood Pressure (BP), Pulse Rate (PR))

    Full Information

    First Posted
    July 15, 2014
    Last Updated
    July 15, 2014
    Sponsor
    Boehringer Ingelheim
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02191254
    Brief Title
    Efficacy and Tolerability of Antistax® in Male and Female Patients Suffering From Chronic Venous Insufficiency
    Official Title
    A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate Efficacy and Tolerability of Antistax® Film Coated Tablets, 360 mg/Day Orally, in Male and Female Patients Suffering From Chronic Venous Insufficiency
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    April 2004 (undefined)
    Primary Completion Date
    October 2004 (Actual)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Boehringer Ingelheim

    4. Oversight

    5. Study Description

    Brief Summary
    Study to assess the efficacy and tolerability of Antistax® film-coated tablets in patients with chronic venous insufficiency (CVI, Clinical condition, Etiology, Anatomic location, Pathophysiology (CEAP) Classification: Clinical Class 3, or 4a)

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Venous Insufficiency

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    Double
    Allocation
    Randomized
    Enrollment
    245 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Antistax®
    Arm Type
    Experimental
    Arm Description
    1 tablet per day for 12 weeks
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Intervention Type
    Drug
    Intervention Name(s)
    Antistax®
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Primary Outcome Measure Information:
    Title
    Change from baseline in limb volume determination
    Description
    water displacement method
    Time Frame
    Baseline, day 84
    Secondary Outcome Measure Information:
    Title
    Changes in limb volume determination
    Description
    water displacement method
    Time Frame
    Baseline, day 21 and day 42
    Title
    Changes in the calf circumference
    Description
    in centimeters
    Time Frame
    Baseline, at day 21, 42 and 84
    Title
    Changes in the ankle circumference
    Description
    in centimeters
    Time Frame
    Baseline, at day 21, 42, and 84
    Title
    Changes in the subjective symptoms of CVI measured by Visual Analogue Scales (VAS)
    Time Frame
    Baseline, at day 21, 42, and 84
    Title
    Global assessment of efficacy by the patient on a 4-point verbal rating scale (VRS)
    Time Frame
    day 84
    Title
    Global assessment of efficacy by the investigator on a 4-point VRS
    Time Frame
    day 84
    Title
    Global assessment of tolerability by the patient on a 4-point VRS
    Time Frame
    day 84
    Title
    Global assessment of tolerability by the investigator on a 4-point VRS
    Time Frame
    Day 84
    Title
    Number of patients with adverse events
    Time Frame
    up to 12 weeks
    Title
    Number of patients with clinically significant changes in laboratory values
    Time Frame
    Baseline, week 12
    Title
    Number of patients with clinically significant changes in vital signs (Blood Pressure (BP), Pulse Rate (PR))
    Time Frame
    Baseline, up to 12 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Male or female 18 years of age or older CVI, Clinical Class 3 (oedema) or 4a (mild skin changes ascribed to venous disease, e.g. pigmentation), according to the CEAP classification Willing and able to give written informed consent prior to participation in the study Exclusion Criteria: Concomitant diseases: Decompensated cardiac insufficiency Oedema not due to venous disease of the legs (e.g., latent cardiac insufficiency, renal insufficiency, lymphoedema, etc) Peripheral arterial disease (ankle/arm pressure index < 0.9) Current acute phlebitis or thrombosis Renal insufficiency (serum creatinine > 1.5 mg/dl) Liver disease (SGPT > 3x upper limit of normal) Other diseases: hyper- or hypocalcaemia, malignancies Anamnestic indications of diabetic microangiopathy or polyneuropathy Drug and/or alcohol abuse Severe climacteric complaints: changes in, or initiation with post-menopausal hormone replacement therapy within the last 3 months Immobility Avalvulia Klippel-Trénaunay-Weber-Syndrome (Naevus varicosis osteohypertrophicus, Haemangiectasia hypertrophicans) State after pulmonary embolism Recognised hypersensitivity to the trial drug ingredients Current florid venous ulcus Clinical indication for a necessary, specific phlebologic acute treatment, e.g. compression treatment, phlebectomy, etc. Previous treatments: Patients who are on compression therapy and/or are wearing support stockings and who optimally benefit from these measures Treatment with venous drugs within the last 2 weeks prior to the intake of study medication Changes in or unstable response to treatment with theophylline, diuretics, cardiac glycosides, ACE inhibitors, calcium antagonists, or laxatives within the last 2 weeks prior to the intake of study medication Concomitant treatment/non-drug therapy exclusion criteria: Other venous drugs apart from the trial medication Venous surgery or sclerotherapy within the last 12 month at the leg used for volumetry Extensive use of laxatives Major surgery requiring full anaesthesia Other exclusion criteria: Previously studied under this protocol Participation in another clinical trial within the previous 90 days or during the present study Patient is investigator, co-investigator, or study nurse in this study Pregnant or nursing women or inadequate birth control methods (this applies to females of childbearing potential only) Patients considered as mentally ill as well as unable to work or with limited working ability, or unable (or only partially able) to follow the spoken or written explanations concerning the trial Patients in a bad general health state according to the investigator's judgement

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    33141449
    Citation
    Martinez-Zapata MJ, Vernooij RW, Simancas-Racines D, Uriona Tuma SM, Stein AT, Moreno Carriles RMM, Vargas E, Bonfill Cosp X. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2020 Nov 3;11(11):CD003229. doi: 10.1002/14651858.CD003229.pub4.
    Results Reference
    derived
    Links:
    URL
    http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1138/1138.4_U05-0299.pdf
    Description
    Related Info

    Learn more about this trial

    Efficacy and Tolerability of Antistax® in Male and Female Patients Suffering From Chronic Venous Insufficiency

    We'll reach out to this number within 24 hrs